logo
welcome
Verywell Health

Verywell Health

Cobenfy: The First New Schizophrenia Drug in Decades

Verywell Health
Summary
Nutrition label

81% Informative

Cobenfy (xanomeline and trospium chloride) targets a different neurotransmitter to indirectly influence dopamine levels.

Cobenf is the first new schizophrenia treatment in over 30 years .

It reduces both positive and negative schizophrenia symptoms, with side effects compared to current medications.

The FDA approved the drug without a boxed warning, which usually accompanies antipsychotics.

Cobenfy will be available in October at a list price of $ 1,850 per month before insurance and rebates.

The company said that the price is in line with other antipsychotic schizophrenia medications.

The drug may also be useful as a treatment for Bipolar I disorder and Alzheimer's disease agitation.